4.5 Article

Epigallocatechin gallate (EGCG) suppresses beta-amyloid-induced neurotoxicity through inhibiting c-Abl/FE65 nuclear translocation and GSK3 beta activation

Journal

NEUROBIOLOGY OF AGING
Volume 30, Issue 1, Pages 81-92

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2007.05.012

Keywords

(-)-Epigallocatechin gallate; beta-amyloid; c-Abl; FE65; Glycogen synthase kinase 3 beta

Funding

  1. National Science Council, Taiwan [NSC94-2320-B002-118]
  2. Novartis Company
  3. Department of Pathology, University of Washington

Ask authors/readers for more resources

Alzheimer's disease (AD) is the most common neurodegenerative disease and is caused by an accumulation of A beta plaque deposits in the brains. Evidence is increasing that green can flavonoids can protect cells from A beta-mediated neurotoxicity. However, the underlying mechanism remains Unclear. Here, We used a human neuronal cell line MC65 conditional expression of all amyloid precursor protein fragment (APP-C99) to investigate the protection mechanism of epigallocatechin gallate (EGCG), the main constituent of green tea. We demonstrated that treatment with EGCG reduced the A beta levels by enhancing endogenous APP nonamyloidogenic proteolytic processing. Furthermore, EGCG also decreased nuclear translocation of c-Abl and blocked APP-C99-dependent GSK3 beta activation, and these inhibitory effects occurred through the interruption of c-Abl/Fe65 interaction. Our results indicated that the neuroprotective action of EGCG may take place through sonic mechanisms other than the promotion of APP nonamyloidogenic proteolysis, as was reported previously. (C) 2007 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available